Trastuzumab should remain as standard of care for HER2-positive breast cancer, trial suggests

Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a researcher.

Read the whole article on Science Daily

More from Science Daily